Press Release Prescribing Information
Campath® Alemtuzumab - For Intravenous Use Only
SEARCH
 
I am taking CAMPATH
I Am Considering Campath
I Am a Caregiver
 
Understanding CLL
Resources and Tools
CamCareTM Assistance Program
 
   Full Prescribing Information (PDF)  |  Contact Us  |  Site Map  
As a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) - See Things in a Whole New Light: Campath First Line - Campath® Alemtuzumab For Intravenous Use Only

B-CLL is a type of blood cancer (leukemia) in which too many white blood cells (lymphocytes) collect in the bone marrow, blood, lymph tissues, and other organs of the body. Because these sick cells live longer than normal cells, they crowd out the healthy cells, causing infection and/or other symptoms.

In appropriate patients, Campath targets these diseased blood cells for destruction.

This website was created to help answer questions about Campath and B-CLL. If you still have questions after reviewing the information on this website, be sure to discuss them with your doctor or nurse. In addition, you may speak with an oncology certified nurse through the free CamCare™ Support Line, which is available 24 hours a day, 7 days a week, 365 days a year: 1-800-473-5832.

  
Indication and Important Safety Information

Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS

Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].

Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].

Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].

The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.

Please see Full Prescribing Information (PDF).